Sign up now for a reminder about our live coverage of the conference.
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg
Don't Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD
Trends in Targeted Temperature Management Before and After 2013, with José López, MD
Diabetes Dialogue: ATTD 2024 Preview
Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes
MRI Treat-to-Target Strategy Fails to Help RA Patients Reach Remission